Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.32 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12403381 | 0.77 | AAK1 (0.31) | — | |
| SCHEMBL10202476 | 0.75 | — | — | |
| SCHEMBL19488494 | 0.75 | — | — | |
| SCHEMBL2595635 | 0.73 | NPC1 (0.54) | NPC1RAB9AKMT2AMEN1CYP1A2 | |
| SCHEMBL19824770 | 0.72 | NPC1 (0.65) | NPC1RAB9AKMT2AMEN1CYP1A2 | |
| Hydrochloric Acid SCHEMBL9994949 | 0.72 | NPC1 (0.52) | NPC1RAB9AKMT2AMEN1CYP1A2 | |
| SCHEMBL19488597 | 0.71 | — | — | |
| SCHEMBL19488467 | 0.71 | SCN10A (0.59) | NPC1RAB9ASCN10A | |
| SCHEMBL12684295 | 0.71 | SCN10A (0.59) | NPC1RAB9ASCN10A | |
| SCHEMBL19528871 | 0.69 | RAB9A (0.47) | NPC1RAB9AKMT2AMEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2601188-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-10-18 | — | — | EP | disclosed |